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FEF25-75 is one of the standard results provided in spirometry reports; however, in adult
asthmatics there is limited information on how this physiological measure relates to clinical
or biological outcomes independently of the FEV1 or the FEV1/FVC ratio.
Purpose
To determine the association between Hankinson’s percent-predicted FEF25-75 (FEF25-75%)
levels with changes in healthcare utilization, respiratory symptom frequency, and biomarkers
of distal airway inflammation.
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Methods
In participants enrolled in the Severe Asthma Research Program 1–2, we compared out-
comes across FEF25-75% quartiles. Multivariable analyses were done to avoid confounding
by demographic characteristics, FEV1, and the FEV1/FVC ratio. In a sensitivity analysis, we
also compared outcomes across participants with FEF25-75% below the lower limit of normal
(LLN) and FEV1/FVC above LLN.
Results
Subjects in the lowest FEF25-75% quartile had greater rates of healthcare utilization and
higher exhaled nitric oxide and sputum eosinophils. In multivariable analysis, being in the
lowest FEF25-75% quartile remained significantly associated with nocturnal symptoms (OR
3.0 [95%CI 1.3–6.9]), persistent symptoms (OR 3.3 [95%CI 1–11], ICU admission for
asthma (3.7 [1.3–10.8]) and blood eosinophil % (0.18 [0.07, 0.29]). In the sensitivity analy-
sis, those with FEF25-75% <LLN had significantly more nocturnal and persistent symptoms,
emergency room visits, higher serum eosinophil levels and increased methacholine
responsiveness.
Conclusions
After controlling for demographic variables, FEV1 and FEV1/FVC, a reduced FEF25-75% is
independently associated with previous ICU admission, persistent symptoms, nocturnal
symptoms, blood eosinophilia and bronchial hyperreactivity. This suggests that in some
asthmatics, a reduced FEF25-75% is an independent biomarker for more severe asthma.
Introduction
Both the diagnosis of asthma and the monitoring of disease severity rely on the use of pulmo-
nary function testing (PFT) data. Though the forced expiratory volume in one second (FEV1)
and the FEV1 to forced vital capacity (FVC) ratio are the most commonly used spirometric
measurements to identify both the presence and degree of airflow obstruction, other values
such as the forced expiratory flow between 25% and 75% of the FVC (FEF25-75) are also com-
monly reported [1]. Although variation in the FEF25-75 was previously thought to reflect
changes exclusively in the small airways (< 2mm) [2–4], subsequent studies using other physi-
ological or radiological parameters have shown that changes in FEF possibly reflect distal air-
flows that involve airways that have greater diameters. More importantly, there is limited
information about its clinical usefulness, including the fact that current guidelines such as
those from the Global Initiative for Asthma (GINA) and the Expert Panel Report 3 of the
National Heart, Lung and Blood Institute do not provide specific recommendations for the use
of FEF25-75 in the evaluation or management of asthma [5,6]. In heterogeneous populations,
FEF25-75 is seldom discordant from FEV1 and FEV1/FVC [7]. However, reduced FEF25-75 in
children with asthma has been shown to be associated with increased asthma severity, need for
systemic steroid use and more frequent exacerbations in the setting of normal FEV1. It is not
known whether these results are also applicable to adult asthmatics [8].
To answer this question, we sought to determine whether the percent predicted FEF25-75
(FEF25-75%) is associated with clinical asthma outcomes among participants of the Severe
Asthma Research Program (SARP). We hypothesized that having a reduced FEF25-75% would
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be associated with increased asthma morbidity independent of and beyond the severity implied
by more traditional markers like FEV1%. We further hypothesized that FEF25-75% would be
associated with biomarkers linked to more distal airway inflammation.
Methods
The study population consisted of participants ages 18 or older from the multi-center SARP
study who met criteria for asthma and also had FEF measurements. Asthma diagnosis was
based on having either a 12% increase in FEV1 after short acting bronchodilator or a 20% drop
in FEV1 after inhalation of methacholine (PC20 25 mg/ml). The SARP 1–2 study has been pre-
viously described in detail [9]. Briefly, the study population consisted of subjects recruited at
SARP participating academic centers through the use of local advertisement and from their
clinics who met eligibility criteria, including being a current nonsmoker with asthma and hav-
ing less than 5 pack-years of tobacco use. Study participants were classified as having either
severe or not severe asthma. According to the American Thoracic Society (ATS) definition,
severe asthma was defined as: at least 1 major criteria: a) Use of high-dose inhaled steroids
for> 50% of the preceding year or b) continuous or near-continuous oral steroids); and at
least 2 minor criteria: a) daily controller medication in addition to inhaled steroids, b) beta ago-
nist required daily or near-daily, c) persistent airway obstruction, d) one or more urgent care
visits for asthma per year, e) 3 or more oral corticosteroid bursts/year, f) clinical deterioration
with reduction in oral steroid dose, and g) near-fatal asthma event in the past. Non-severe asth-
matics included those with moderate (pre bronchodilator FEV1< 80% with or without use of
inhaled corticosteroids (CS)) or mild (FEV1 80% with or without use of inhaled CS) asthma.
Clinical Data
After signing informed consent, study participants provided demographic information, smok-
ing history, past medical history and frequency of respiratory symptoms in the 3 months pre-
ceding enrollment, including cough, sputum production, chest tightness, nighttime asthma
symptoms, wheezing, and shortness of breath. Subjects also completed the Juniper Asthma
Quality of Life Questionnaire (AQLQ). As this specific project was performed as secondary
analysis of the above data following de-identification, no further patient consent or institu-
tional review board approval was required.
Allergy Skin Test
All participants underwent allergy skin testing for tree mix, grass mix, ragweed, weed mix,
dogs, cats, molds, dust mites, and cockroach. To control for validity, diluting fluid and hista-
mine were respectively used as negative and positive controls. Presence of atopy was defined as
having at least one skin test reaction of3 mm and greater than the saline control.
Lung Function testing
Spirometry was done following ATS guidelines[10]. Post bronchodilator FEV1 was recorded as
the maximum bronchodilator change between 4 and 8 puffs of albuterol. Patients with a base-
line FEV1> 50% and FEV1 1.5L underwent methacholine challenge, following a 7-dose
algorithm of incremental doses from 0.078mg/ml to maximum of 25 mg/ml. A provocation
concentration (PC20) of<16 mg/ml was considered positive. This high value was chosen
because of the high and prolonged steroid doses in the population. Because of FEV1 criteria,
methacholine challenges were only done to a subset of the subjects. FEF25-75% was calculated
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using Hankinson’s regression models for each sex and by race [11]. Exhaled nitric oxide (eNO)
was measured online following ATS and ERS standards [12].
Statistical Analysis
The FEF25-75% distribution was divided into quartiles to determine how the variability in this
measure associates with changes in healthcare utilization, frequency of respiratory symptoms
and biomarkers of distal airway inflammation. Healthcare utilization included emergency
department (ED) visits, hospitalizations and intensive care unit (ICU) admissions for asthma.
The frequency of respiratory symptoms was defined as a binary variable for having or not hav-
ing symptoms at least twice or more per week. Continuous parametric and non-parametric
data were respectively compared across FEF25-75% quartiles using one way ANOVA or Kruskal
Wallis tests with Bonferroni pairwise comparisons. The Chi2 test was used to compare the dis-
tribution of categories.
To evaluate for possible confounders, we performed logistic regression analysis that
included the following models: a) univariable, b) adjusted for demographic factors (age, gender,
BMI, race), and c) full model adjusted for demographic variables + FEV1% predicted and the
FEV1/FVC ratio. The covariable model selection was based a priori and whether their p value
was< 0.1 or the model’s estimate changed by 10%. Given the high degree of correlation
between FEF and FEV1 or the FEV1/FVC ratio, all models were evaluated for collinearity using
the variance inflation factor (VIF). Due to the fact that in severe asthmatics, FVC accounts for
most of the FEV1 reversal after bronchodilation due to air trapping [13], a separate multivariate
analysis was run with adjustment for FVC rather than FEV1 (S3 Table); both could not be
adjusted for in the same model due to collinearity. We also performed a sensitivity analysis to
determine the study outcomes of discordant subjects with low FEF25-75% but no airway
obstruction, defined as having FEF25-75<LLN with FEV1/FVC> the lower limit of normal
(LLN). All statistics were done using Stata 13.0 (College Park, Tx).
Results
The characteristics of the study population are shown in Table 1, which consisted of 829
participants, of whom the majority was Caucasian, female and overweight. With decreasing
FEF25-75% quartiles, there was a greater proportion of African American race, larger BMI, lon-
ger duration of asthma and a higher proportion of moderate to severe asthmatics. There was
also a strong association between FEF25-75% quartiles with increased medication use health
care utilization, eNO, IgE and sputum eosinophil proportions. Similarly, participants in the
lower quartile distribution were more likely to have required an oral corticosteroid burst, to be
seen in the emergency room or to be hospitalized for asthma. Those in the lowest FEF25-75%
quartile had the highest likelihood of having been previously intubated for asthma. With
progressive FEF25-75% decline, there was also a significant reduction in FVC, FEV1 and the
FEV1/FVC ratio as shown in Table 2. Adjustment for FVC rather than FEV1 did not signifi-
cantly change the results of the multivariate analysis (S3 Table).
Multivariable analyses
Respiratory symptoms. In the univariable analysis (S1 Table), compared to highest refer-
ent FEF25-75% quartile (median 92.5 (IQR [80.1, 101.1]) category, the odds of having persistent
respiratory symptoms increased in association with lower FEF25-75% quartiles and remained
largely significant after adjustment for age, BMI, sex, duration of asthma and ever smoking;
however, after adjustment for FEV1 percent predicted and the FEV1/FVC ratio, only nocturnal
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symptoms and persistent symptoms remained significantly associated with the lowest
FEF25-75% quartile (median 25.6 [IQR 20.4, 32.2]) as shown in Table 3 and Fig 1A.
Healthcare utilization. In the univariable analysis, compared to the referent category, the
odds of ever requiring hospitalizations, ED visits or ICU care increased in relation to lower
Table 1. Characteristics of the study population by the FEF25-75% quartile distribution.
Q1 Q2 Q3 Q4 P-value
Overall 88 (74–146) 64 (56–74) 46 (37–55) 27 (9–37)
N = 829 N = 207 N = 207 N = 208 N = 207
Demographics
Age 36.8 (25.5, 46.6) 32.6 (22.2, 38.9) 35.3 (25.6, 42.0) 37.6 (26.7, 47.7) 41.7 (32.2, 49.6) P<0.0001
Sex—Female 65.1% 67.1% 70.5% 64.4% 58.4% P = .07
Sex—Male 34.9% 32.9% 29.5% 35.6% 41.6%
Race—White 64.9% 74.4% 69.6% 61.1% 54.6% P<0.0001
Race—Black 27.4% 15.0% 25.1% 31.7% 37.7%
Race—Other 7.7% 10.6% 5.3% 7.2% 7.7%
BMI 29.9 (23.9, 34.2) 28.0 (22.5, 32.5) 29.6 (23.8, 33.0) 30.8 (24.6, 35.0) 31.3 (25.1, 35.9) P<0.0001
Duration of asthma (yrs) 21.8 (11.8, 30.6) 17.9 (8.5, 23.8) 19.9 (10.6, 27.1) 23.0 (12.8, 32.1) 26.3 (15.6, 35.9) P<0.0001
Ever smoked 20.7% 18.0% 20.3% 21.2% 23.2% P = 0.6
Biomarkers
Exhaled NO (ppb) 38.0 (15.6, 48.1) 31.1 (13.5, 36.6) 37.1 (14.1, 49.7) 40.1 (17.8, 52.2) 43.8 (17.0, 49.3) P<0.01*
IgE (IU/mL blood) 324 (54, 334) 197 (42, 226) 316 (52, 355) 401 (64, 362) 384 (56, 385) P<0.05*
Eosinophil % (blood) 3.93 (2, 5) 3.40 (1.55, 5) 3.95 (2, 5) 3.66 (2, 5) 4.72 (2. 6) P<0.01**
Sputum eosinophil % 4.89 (0.2, 4.1) 3.22 (0.001, 1.9) 3.08 (0.2, 2.8) 3.66 (0.3, 4.0) 9.59 (0.6, 8.6) P<0.001**
PC20 1.15 (0.42, 3.89) 2.25 (0.89, 6.48) 1.28 (0.53, 3.99) 0.84 (0.27, 2.42) 0.46 (0.19, 1.44) P<0.0001*
Outcomes
ER for breathing ever 67.9% 61.8% 58.5% 68.1% 83.1% P<0.001
Spent night in hospital ever 42.4% 33.3% 30.4% 38.8% 67.2% P<0.001
ICU ever 15.9% 6.4% 7.8% 14.7% 34.8% P<0.001
Intubated ever 8.3% 4.8% 5.8% 4.8% 18.0% P<0.001
Footnote: Continuous variables are shown as median (Inter quartile range). Categorical variables shown as percentage of total. Q: quartile, BMI: body
mass index, NO: nitric oxide, WBC: white blood cell, PC20: provocation challenge, ER: emergency room, ICU: intensive care unit.
* P value calculated from log transformed data
** P value calculated from Kruskal-Wallis test
doi:10.1371/journal.pone.0145476.t001
Table 2. Lung function parameters by the FEF25-75% quartile distribution.
Overall Q1 Q2 Q3 Q4
N = 829 N = 207 N = 207 N = 208 N = 207
FEV1 (% predicted) 78.6 (66, 92) 97.2 (90, 104) 87.0 (80, 94) 74.5 (67, 81) 55.9 (46, 66)
FVC (% predicted) 89.4 (79, 101) 97.6 (89, 106) 94.5 (84, 103) 88.1 (79, 97) 77.4 (64, 89)
FEV1/FVC 0.72 (0.65, 0.80) 0.83 (0.80, 0.87) 0.76 (0.73, 0.80) 0.70 (0.66, 0.74) 0.59 (0.53, 0.65)
FEF25-75 (% predicted) 57.0 (37.2, 73.8) 92.5 (80.1, 101.1) 64.0 (59.0, 68.5) 46.0 (41.8, 50.8) 25.6 (20.4, 32.2)
Footnote: Values shown as median (Inter quartile range). Q: quartile, FEV1: forced expiratory volume in one second, FVC: forced vital capacity, FEF25-
75: forced expiratory ﬂow between 25% and 75% of FVC.
doi:10.1371/journal.pone.0145476.t002
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FEF25-75% quartiles (S1 Table). After adjusting for demographics, these associations were
attenuated but remained significant. After adjusting for FEV1% and the FEV1/FVC ratio, only
those in the lowest FEF25-75% quartile had a significantly increased odds ratio (OR) of ever hav-
ing an ICU admission for asthma (Table 3, Fig 1B).
Biomarkers of allergic, airway inflammation and bronchial hyperactivity. In the uni-
variable analysis, lower FEF25-75% quartiles were significantly associated with log-transformed
eNO, IgE, PC20, blood and sputum eosinophils (S1 Table). After adjustment for demographics,
these remained significant with the exception of blood eosinophilia. In the fully adjusted
model, the 3rd FEF25-75% quartile was associated with IgE, eNO, PC20, and marginally with
sputum eosinophils. In the lowest quartile, only blood eosinophils and PC20 remained signifi-
cant (Table 3 and Fig 1C), though a trend towards increasing IgE, eNO and sputum eosino-
philia remained.
Sensitivity analysis on patients with discordant FEF25-75 and FEV1/FVC. Compared to
asthmatics with an FEF25-75>LLN and FEV1/FVC>LLN, those with a reduced FEF25-75
<LLN but FEV1/FVC>LLN, had significantly increased nocturnal symptoms and persistent
symptoms. They were also more likely to visit the emergency room, to have serum eosinophilia
and bronchial hyperreactivity (S2 Table).
Discussion
In this cross sectional study of SARP participants, reduced FEF25-75% was associated with
increased frequency of respiratory symptoms, greater healthcare utilization and higher levels of
biomarkers of distal airway inflammation. Although many of these associations were attenu-
ated by adjusting for FEV1% and the FEV1/FVC ratio, having a reduced FEF25-75% was inde-
pendently related to more frequent nocturnal and persistent symptoms, ICU admission for
asthma, higher eNO, greater bronchial hyperresponsiveness and higher sputum eosinophil per-
centage. Further, among patients with an FEV1/FVC ratio above the lower limit of normal,
having an FEF25-75 below the LLN was associated with increased symptom burden, healthcare
utilization, serum eosinophilia and bronchial hyperreactivity. Together, these results show for
Table 3. Multivariable analysis of respiratory symptoms, healthcare utilization and biomarkers by FEF25-75% quartile distribution.
Symptoms Wheeze SOB Nocturnal Sx Sputum production Chest tightness Persistent Sx
Reference (FEF Q1) 1.00 1.00 1.00 1.00 1.00 1.00
FEF Q2 1.32 (0.83, 2.08) 1.21 (0.75, 1.95) 1.72 (1.09, 2.72) 1.23 (0.79, 1.91) 0.78 (0.49, 1.24) 1.54 (0.72, 3.30)
FEF Q3 1.40 (0.78, 2.53) 1.27 (0.67, 2.40) 1.75 (0.99, 3.08) 1.17 (0.67, 2.03) 0.60 (0.33, 1.09) 2.50 (1.05, 5.99)
FEF Q4 1.97 (0.82, 4.73) 2.21 (0.84, 5.79) 3.01 (1.32, 6.89) 1.6 (0.72, 3.58) 0.49 (0.21, 1.15) 3.32 (1.00, 11.03)
Healthcare Usage ER ever Spent night hosp ever ICU ever Ever intubated
Reference (FEF Q1) 1.00 1.00 1.00 1.00
FEF Q2 0.68 (0.42, 1.10) 0.60 (0.37, 0.98) 1.04 (0.47, 2.31) 0.91 (0.37, 2.27)
FEF Q3 0.81 (0.43, 1.52) 0.63 (0.34, 1.14) 1.64 (0.71, 3.78) 0.55 (0.19, 1.62)
FEF Q4 1.48 (0.56, 3.91) 1.38 (0.58, 3.29) 3.73 (1.28, 10.83) 1.63 (0.45, 5.91)
Biomarkers eNO IgE Blood Eos Sputum Eos PC20
Reference (FEF Q1) 0 0 0 0 0
FEF Q2 3.37 (-5.05, 11.78) 133.94 (-42.11, 309.99) 0.07 (0.01, 0.13) -0.90 (-4.07, 2.27) -1.53 (-2.66, -0.39)
FEF Q3 4.85 (-5.84, 15.56) 255.44 (34.19, 476.69) 0.07 (-0.01, 0.14) -0.82 (-4.81, 3.17) -2.86 (-4.43, -1.29)
FEF Q4 3.38 (-12.28, 19.03) 281.21 (-37.73, 600.14) 0.18 (0.07, 0.29) 3.75 (-2.07, 9.57) -3.12 (-5.34, -0.90)
Footnote: Multivariable logistic (odds ratio) and linear regression (beta coefﬁcient) models were adjusted for age, sex, body mass index, duration of
asthma, history of smoking, FEV1 and FEV1/FVC. Q: quartile, SOB: shortness of breath, Sx: symptoms, ER: emergency room, ICU: intensive care unit,
eNO: exhaled nitric oxide, Eos: eosinophils, PC20: provocation challenge, FEF quartiles: Q1: 88 (74–146), Q2: 64 (56–74), Q3: 46 (37–55), Q4: 27 (9–37)
doi:10.1371/journal.pone.0145476.t003
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the first time in adults with asthma, that having a low FEF25-75% identifies a group of patients
with higher morbidity and elevated biomarkers of distal airway inflammation.
According to the European Respiratory Society (ERS) and the American Thoracic Society
(ATS) task force for standardization of lung function testing, the FEF25-75 is defined as the
mean forced expiratory flow between the 25% and 75% of the FVC [14,15], which some have
interpreted as a quantitative measure of small airways (<2mm) obstruction [4]. Indeed, since
the 1970s FEF25-75% rates were proposed to be a marker of small airway obstruction and a
more sensitive way to detect early stages of obstructive airway disease. However, others have
argued that FEF25-75% is highly variable and neither sufficiently sensitive nor specific to diag-
nose obstructive lung disease [16]. Moreover, FEF25-75% has not been shown to correlate with
other physiologic or histologic measures of distal lung inflammation [16]. Using computed
tomography airway morphometric analysis, FEF25-75% has been shown to be moderately and
inversely correlated with the bronchial wall area (WA) and WA corrected for body surface
Fig 1. Adjusted odds ratios and beta coefficients of respiratory symptom frequency (a), healthcare
utilization (b), biomarkers and bronchial hyperresponsiveness (c). Footnote: Multivariable logistic and
regression models adjusted for: for age, sex, body mass index, duration of asthma, history of smoking, FEV1
and FEV1/FVC. Error bars represent 95% confidence intervals.
doi:10.1371/journal.pone.0145476.g001
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area, though not exclusively in the small airways [17]. Although it is possible that FEF25-75%
predominantly reflects flows derived from more distal airways, there is insufficient data to sup-
port the concept that variability in this measure is specific to small airway changes. Despite
these limitations, FEF25-75% continues to be part of the standard spirometry report. More
importantly, there are no recommendations as to how reductions in this measure should be
taken into consideration for asthma treatment or for risk stratification.
Unlike Quanjer et al[7] who have argued that FEF25-75% does not aid clinical decision mak-
ing, our results support a different conclusion. Although we also found the percentage of dis-
cordant cases (low FEF25-75% with a normal FEV1/FVC) is relatively small, FEF was
independently associated with several clinical, inflammatory and healthcare outcomes. Further,
the study by Quanjer et al was unable to examine these associations, as their study did not
include any non-physiological clinical outcomes.
In children, a low FEF25-75% has been associated with greater odds for systemic steroids and
ED visits, despite having a normal FEV1 [18]. Similarly, our study found that even when con-
trolling for FEV1 and the FEV1/FVC ratio, asthmatics with lower FEF25-75% have greater odds
of having been admitted to the ICU and to have persistent respiratory symptoms. In addition,
we have shown that lower FEF25-75% is independently associated with eNO. As shown by
Dweik et al[19], eNO is associated with increased asthma morbidity when levels are above
35 ppb. When taken into consideration with increased persistent and nocturnal symptoms, we
speculate that FEF25-75% is indeed related to more distal airway inflammation either not fully
captured or not yet evident by FEV1; however, further work must be done to evaluate this
hypothesis. If proven in prospective investigation, the clinical implications would include both
prognosis and identification of an at-risk asthma population for more intensive therapy.
There are significant limitations that need to be considered when evaluating the results
from this study. First, given the cross-sectional nature of this study, no causal implications can
be made between FEF25-75% and asthma severity. This question will need to be answered in the
ongoing longitudinal SARP 3 study. Also, reliance on questionnaire responses may contribute
to recall bias, though this should be a non-differential bias with regards to the FEF25-75% distri-
butions. Additionally, our results may lack external validity, as the SARP study population is
enriched with a higher proportion of participants with severe asthma and is not representative
of the general adult asthma population. Though this limits the generalization of these findings,
it should be noted that SARP still represents a broader spectrum of asthma than most studies,
which may help with distinguishing effects.
Conclusions
Independent of FEV1 and FEV1/FVC, FEF25-75% predicted identifies a population of adult
asthmatics with more severe symptoms, greater health care utilization and elevated biomarkers
of distal airway inflammation. Further research is needed to determine if this information can
be used clinically to guide treatment decisions or for prognostic evaluation; these questions are
currently undergoing longitudinal analysis within SARP 3.
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S1 Table. Symptoms, Health Care Utilization and Biomarkers across FEF Quartiles unad-
justed and adjusted for demographics. Footnote: Multivariable logistic (odds ratio) and linear
regression (beta coefficient) models were adjusted for age, sex, body mass index, duration of
asthma, history of smoking, FEV1 and FEV1/FVC. Bolded values represent p-values< 0.05.
Multivariate analysis odds ratios and 95% confidence intervals. Linear regression beta coef-
ficients and 95% confidence intervals. Q: quartile, SOB: shortness of breath, Sx: symptoms, ER:
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